• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Faricimab may improve visual acuity in patients with diabetic macular edema

byNeel MistryandTeddy Guo
March 8, 2022
in Chronic Disease, Endocrinology, Ophthalmology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Faricimab every 8 weeks and faricimab per personalized treatment interval (PTI) were noninferior to aflibercept for mean change in visual acuity.

2. Adverse events between faricimab every 8 weeks, faricimab PTI, and aflibercept every 8 weeks were comparable.

Evidence Rating Level: 1 (Excellent)

Study Rundown: First-line treatment for diabetic macular edema (DME) includes anti-vascular endothelial growth factor (VEGF) medications such as aflibercept. However, this treatment involves close monitoring with regular injections every 4-8 weeks. Faricimab is an angiopoietin-2 and VEGF bispecific antibody that may be used in the management of patients with DME, although little is known at this time. This study is an amalgamation of two randomized, double-masked, phase 3 trials (YOSEMITE and RHINE) that were conducted to assess the safety and efficacy of faricimab in patients with DME. The primary outcome was mean change in best-corrected visual acuity (BCVA) from baseline to 52 weeks while key secondary outcome included the proportion of patients receiving faricimab at regular 4-week intervals. According to study results, faricimab every eight weeks and faricimab per personalized treatment interval (PTI) were non-inferior to aflibercept every weight weeks for visual acuity at 52 weeks. This study was strengthened by pooling of results from two separate randomized controlled trials.

Click to read the study in The Lancet

Relevant Reading: Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial

In-depth [randomized-controlled trial]: Between Sept 5, 2018, and Sept 19, 2019 (YOSEMITE) and Oct 9, 2018, and Sept 20, 2019 (RHINE), 3247 patients were screened for eligibility across 353 sites worldwide. Included were those ≥18 years of age with center-involving diabetic macular edema. Altogether, 1891 patients (940 in YOSEMITE and 951 in RHINE) were included in the intention-to-treat analysis (632 to faricimab every 8 weeks, 632 to faricimab PTI, and 627 to aflibercept every 8 weeks). Regarding the primary outcome of mean change in visual acuity, faricimab every 8 weeks (YOSEMITE 10.7 ETDRS letters and RHINE 11.8 ETDRS letters) and faricimab PTI (YOSEMITE 11.6 ETDRS letters and RHINE 10.8 ETDRS letters) were non-inferior to aflibercept every 8 weeks (YOSEMITE 10.9 ETDRS letters and RHINE 10.3 ETDRS letters). In addition, the proportion of adverse events between faricimab every 8 weeks (YOSEMITE 31%, RHINE 43%), faricimab PTI (YOSEMITE 34%, RHINE 37%), and aflibercept every 8 weeks (YOSEMITE 33%, RHINE 36%) were comparable. Findings from this study suggest that faricimab is effective for treatment of diabetic macular edema and its use should be considered in clinical practice.

RELATED REPORTS

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: afliberceptdiabetesdiabetes mellitusdiabetic macular edemadiabetic retinopathyendocrinologyfaricimabmacular edemaOphthalmologyType 1 Diabetes MellitusType 2 Diabetes Mellitus
Previous Post

Intensive blood pressure control associated with increased cerebral blood flow in patients with hypertension – the SPRINT trial

Next Post

#VisualAbstract: Endotracheal intubation offers no benefit over supraglottic airway in patients with out-of-hospital return of spontaneous circulation

RelatedReports

Type 2 diabetes associated with reduction in disability-free life years
Chronic Disease

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

January 16, 2023
Pediatric DKA associated with recent acute care visits
Cardiology

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

January 11, 2023
Cardiology

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

December 26, 2022
Solitary kidney not associated with contrast-induced nephropathy
Chronic Disease

Dapagliflozin reduces the risk of hospitalization in patients with chronic kidney disease

December 26, 2022
Next Post
#VisualAbstract: Endotracheal intubation offers no benefit over supraglottic airway in patients with out-of-hospital return of spontaneous circulation

#VisualAbstract: Endotracheal intubation offers no benefit over supraglottic airway in patients with out-of-hospital return of spontaneous circulation

Female incontinence associated with physical activity

Injury risk in trail running is associated with extrinsic and intrinsic factors

Of Background Image

Melioidosis outbreak is associated with imported aromatherapy spray

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Community-based adult vision screening program increases access to eye care
  • Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options